{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Visual+Function&page=95",
    "query": {
      "condition": "Visual Function",
      "page": 95
    },
    "page_size": 10
  },
  "pagination": {
    "page": 95,
    "page_size": 10,
    "total_count": 2377,
    "total_pages": 238,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Visual+Function&page=96&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Visual+Function&page=94&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T16:49:24.668Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00074191",
      "title": "Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "lomustine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "procarbazine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2000-01",
      "completion_date": "2000-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074191"
    },
    {
      "nct_id": "NCT02829268",
      "title": "A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Wolfram Syndrome",
        "Diabetes Mellitus",
        "Optic Nerve Atrophy",
        "Ataxia"
      ],
      "interventions": [
        {
          "name": "dantrolene sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 21,
      "start_date": "2017-01",
      "completion_date": "2023-02",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829268"
    },
    {
      "nct_id": "NCT00854750",
      "title": "Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ACTHAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elliot Frohman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-05",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-04-22",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00854750"
    },
    {
      "nct_id": "NCT05165290",
      "title": "Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Elevated Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Latanoprost ophthalmic solution, 0.005%",
          "type": "DRUG"
        },
        {
          "name": "TC-002 latanoprost ophthalmic solution, 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TearClear Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2021-11-29",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 20,
      "location_summary": "Garden Grove, California • Glendale, California • Mission Hills, California + 16 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05165290"
    },
    {
      "nct_id": "NCT02938078",
      "title": "Ocular Comfort and Inflammation in Lid Hygiene Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "Avenova Lid Cleanser",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Minnesota Eye Consultants, P.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2016-10",
      "completion_date": "2018-08-24",
      "has_results": false,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Bloomington, Minnesota",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02938078"
    },
    {
      "nct_id": "NCT03919708",
      "title": "Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amblyopia",
        "Strabismus"
      ],
      "interventions": [
        {
          "name": "Retinal Birefringence Imager",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rebiscan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "2 Years to 8 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-02-04",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03919708"
    },
    {
      "nct_id": "NCT00494676",
      "title": "Clinical Trial of Peripheral Prism Glasses for Hemianopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Homonymous Hemianopia"
      ],
      "interventions": [
        {
          "name": "High power (57 prism diopter) peripheral prism glasses",
          "type": "DEVICE"
        },
        {
          "name": "Low power sham peripheral prism glasses",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Alexandra Bowers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2007-09",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Jupiter, Florida + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494676"
    },
    {
      "nct_id": "NCT04734210",
      "title": "Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "0.02% Betamethasone Sodium Phosphate",
          "type": "DRUG"
        },
        {
          "name": "0.04% Betamethasone Sodium Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2021-01-07",
      "completion_date": "2022-10-12",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 28,
      "location_summary": "Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04734210"
    },
    {
      "nct_id": "NCT02558400",
      "title": "Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PG324 Ophthalmic Solution 0.02%/0.005%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil (AR-13324) Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost Ophthalmic Solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 718,
      "start_date": "2015-09-18",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02558400"
    },
    {
      "nct_id": "NCT01212861",
      "title": "Surgical Treatment of Refractory Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Suprachoroidal Dissection Instrument (SDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "iScience Interventional Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2010-08",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-09-12",
      "last_synced_at": "2026-10-24T16:49:24.668Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01212861"
    }
  ]
}